Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Operating Expenses (2021 - 2025)

Historic Operating Expenses for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $2.3 million.

  • InMed Pharmaceuticals' Operating Expenses fell 1576.88% to $2.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.2 million, marking a year-over-year decrease of 372.71%. This contributed to the annual value of $9.7 million for FY2025, which is 382.68% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Operating Expenses of $2.3 million as of Q4 2025, which was down 1576.88% from $2.2 million recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Operating Expenses ranged from a high of $6.8 million in Q2 2022 and a low of $2.0 million during Q4 2023
  • In the last 5 years, InMed Pharmaceuticals' Operating Expenses had a median value of $2.4 million in 2022 and averaged $2.8 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Operating Expenses tumbled by 6963.63% in 2023, and later surged by 3787.63% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Operating Expenses stood at $4.4 million in 2021, then tumbled by 46.99% to $2.3 million in 2022, then fell by 16.03% to $2.0 million in 2023, then skyrocketed by 37.88% to $2.7 million in 2024, then fell by 15.77% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q4 2025, $2.2 million for Q3 2025, and $2.4 million during Q2 2025.